CPT 81425: Whole Genome Sequencing for Diagnostic Evaluation
Commercial payers pay $4542 on average nationally for this procedure.
CPT code 81425 describes a clinical laboratory service performing comprehensive whole genome sequencing to analyze the patient's entire genomic sequence for genetic variants that may explain an unexplained disorder or syndrome; this is a genomic sequencing diagnostic test typically performed as a clinical diagnostic laboratory service with the typical site of service being an outpatient or inpatient clinical laboratory affiliated with a hospital or specialized genetics testing center.
Customize your policy alerts
Sign up for cpt 81425 policy alerts
Get alerted when payer policies referencing 81425 are released or updated.
Monitor payer policy activity
National Reimbursement Benchmarks
National commercial reimbursement for CPT 81425 centers around the BUCA average commercial benchmark of $4,542.30, with payers showing meaningful variation around that midpoint. Blue Cross Blue Shield has one of the widest dispersions between the 25th and 75th percentiles (P75 $6,006.40 minus P25 $3,217.00 = $2,789.40), closely followed by Cigna (P75 $6,643.00 minus P25 $2,581.40 = $4,061.60) and UnitedHealth Group (P75 $5,031.20 minus P25 $2,113.10 = $2,918.10). Aetna displays a narrower interquartile spread (P75 $5,031.20 minus P25 $1,720.70 = $3,310.50) relative to Cigna and UnitedHealth Group but wider than some peers.
Dispersion highlights that Cigna exhibits the widest IQR at $4,061.60, signaling greater variability in mid‑range commercial payments, while Blue Cross Blue Shield and UnitedHealth Group also show substantial spreads of $2,789.40 and $2,918.10 respectively. BUCA’s average of $4,542.30 sits near payer medians overall, underscoring that commercial pricing for this code clusters around the mid single‑ to low five‑thousand dollar range despite notable inter‑payer variability.